Mink Therapeutics

Yahoo Finance • 11 hours ago

MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference

NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and tre... Full story

Yahoo Finance • 22 days ago

Wall Street Stabilizes After Oil-Driven Volatility as US Equity Futures Waver Pre-Bell

US equity futures were cautiously lower ahead of Tuesday's opening bell as investor sentiment steadi PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 23 days ago

MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers

Selected as a C-Further program with up to ~$1.1 million in non-dilutive, aggregate payments to advance IND-enabling development, with potential for meaningful double-digit downstream commercial revenue participation NEW YORK, March 10,... Full story

Yahoo Finance • 5 months ago

MiNK Therapeutics GAAP EPS of -$0.65 beats by $0.20

* MiNK Therapeutics press release [https://seekingalpha.com/pr/20307971-mink-therapeutics-reports-q3-2025-results-and-accelerates-inkt-platform-toward-pivotal] (INKT [https://seekingalpha.com/symbol/INKT]): Q3 GAAP EPS of -$0.65 beats by... Full story

Yahoo Finance • 5 months ago

MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation

New clinical data show durable remissions and long-tail survivors including >2-year complete remissions in chemotherapy- and checkpoint-refractory cancersGVHD trial launching through non-dilutive funding from NIH- and philanthropic grantsL... Full story

Yahoo Finance • 5 months ago

MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025

Durable survival and deep, lasting remissions in checkpoint-refractory, heavily pretreated cancers with median OS of ~23 months with agenT-797 plus anti-PD-1Evidence of immune activation and tumor-immune remodeling underscore agenT-797’s p... Full story

Yahoo Finance • 5 months ago

MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development

NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, t... Full story

Yahoo Finance • 6 months ago

MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA

NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical company pioneering invariant natural killer T (iNKT) cell therapies, today announced that its President and Chief Exe... Full story

Yahoo Finance • 6 months ago

MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development

Imminent launch of grant-funded clinical trial in graft-versus-host disease (GVHD)Advancing clinical program in severe pulmonary inflammatory disease NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (Nasdaq: INKT), a... Full story

Yahoo Finance • 8 months ago

MiNK Therapeutics Inc (NASDAQ:INKT) Reports Wider Q2 2025 Loss, Advances Clinical Pipeline Amid Market Caution

MiNK Therapeutics Inc (NASDAQ:INKT [https://www.chartmill.com/stock/quote/INKT]) reported its second-quarter 2025 financial results, missing analyst expectations on earnings per share (EPS) while maintaining no revenue, as anticipated. The... Full story

Yahoo Finance • 8 months ago

MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results

Cash runway extended to deliver clinical program in GVHD and Ph2 results in 2L Gastric CancerDepartment of Defense STTR Grant to advance INKTs in GVHD announced; program advancingNew clinical grant awarded to launch AgenT-797 in GvHD clini... Full story

Yahoo Finance • 8 months ago

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report

NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural k... Full story

Yahoo Finance • 9 months ago

MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy

NEW YORK, July 15, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies, today announced the publication of a p... Full story

Yahoo Finance • 9 months ago

Agenus unit, MiNK surges after peer-reviewed data for lead drug

* Shares of MiNK Therapeutics (NASDAQ:INKT [https://seekingalpha.com/symbol/INKT]) climbed over 500% in the morning hours on Friday after the nano-cap cell therapy developer, which is a unit of Agenus (NASDAQ:AGEN [https://seekingalpha.c... Full story

Yahoo Finance • 9 months ago

MiNK Therapeutics stock soars after cancer remission breakthrough

Investing.com -- MiNK Therapeutics, Inc. (NASDAQ:INKT) stock soared 200% after the company announced a complete remission in a patient with metastatic testicular cancer following treatment with its allogeneic iNKT cell therapy, agenT-797.... Full story

Yahoo Finance • 9 months ago

MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer

NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced the pub... Full story

Yahoo Finance • 10 months ago

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced that it... Full story

Yahoo Finance • 10 months ago

MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced it has... Full story

Yahoo Finance • last year

MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, tod... Full story

Yahoo Finance • last year

MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural... Full story